NCT04213469View on ClinicalTrials.gov

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 13, 2020

Primary Completion Date

November 1, 2021

Study Completion Date

November 10, 2023

Conditions
B-cell Lymphoma
Interventions
BIOLOGICAL

PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells

Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1

Trial Locations (1)

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
collaborator

First Affiliated Hospital of Zhejiang University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT04213469 - PD1-CD19-CART in Patients With r/r B-cell Lymphoma | Biotech Hunter | Biotech Hunter